In contrast to the Mps1 inhibitor studies, recent studies reveal that complete regression of basal-a/TNBC breast tumors in xenograft models can be achieved without significant body weight loss by targeting a different mitotic checkpoint protein that regulates another aspect of the checkpoint process (CENP-E) [31]. The gene discussed is TTK; the disease is breast neoplasm.